SCHEMBL17895272

SCHEMBL17895272

O=C(CNc1nc2ccccc2n2c(-c3ccc(O)c(O)c3)cnc12)NC(CO)(CO)CO

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
ADORA1 P30542 2/20 0.37
ADORA2A P29274 1/20 0.37
ALPL P05186 1/20 0.37
ALPG P10696 1/20 0.37
IKBKB O14920 2/20 0.35
BRD4 O60885 9/20 0.34
CHUK O15111 1/20 0.34
MIF P14174 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CTSD P07339 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895300 0.86 MAOA (0.42) ALDH1A1ADORA1IKBKBBRD4
SCHEMBL17895085 0.79 IKBKB (0.48) ADORA1ADORA2AIKBKBBRD4CHUK
SCHEMBL19786871 0.78 IKBKB (0.40) ADORA1ADORA2AIKBKBBRD4CHUK
SCHEMBL17895237 0.78 BRD4 (0.47) ADORA1ADORA2AIKBKBBRD4CHUK
SCHEMBL17895199 0.77 IKBKB (0.46) ADORA1ADORA2AALPLALPGIKBKB
SCHEMBL22099675 0.76 BRD4 (0.40) BRD4
SCHEMBL22099671 0.76 BRD4 (0.40) BRD4
SCHEMBL17895072 0.76 BRD4 (0.49) IKBKBBRD4CHUK
SCHEMBL19786798 0.74 ADORA2A (0.37) ADORA1ADORA2AALPLALPGIKBKB
SCHEMBL17895242 0.72 ADORA2A (0.45) ADORA1ADORA2AIKBKBCHUKMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP claimed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP claimed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO claimed
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
US-20180016278-A1 Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) 2018-01-18 US disclosed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP disclosed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer NQO1, NQO2, ABL1 ALDH1A1 163/4885ADORA1 1036/4885ADORA2A 1104/4885
US-20180016278-A1 Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer NQO1, NQO2, ABL1 ALDH1A1 163/4885ADORA1 1036/4885ADORA2A 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.